Literaturverzeichnis 2017 / 2018


Hier finden Sie die Literaturangaben zu den Übersichtsartikeln der Zeitschrift für Infektionstherapie aus den Jahren 2017 und 2018



Heft 2 / 2018

Heft 1 / 2018

Heft 6 / 2017

Heft 3 / 2017

Heft 2 / 2017

Heft 1 / 2017

Literaturangaben zum Übersichtsartikel aus

Heft 1 / 2018 der Zeitschrift für Infektionstherapie

Entwicklung neuer Antibiotika - wo geht die Reise hin?

1. Theuretzbacher U. Antibiotic innovation for future public health needs. Clin Microbiol Infect. 2017 Oct;23(10):713-717.


2. O'Dwyer K et al. Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 2015 Jan;59(1):289-98 FREE FULL TEXT


3. Tacconelli E et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Inf Dis 2017 (online, 21. Dezember 2017) PubMed abstract


4. Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect. 2017 Oct;23(10):704-712 PubMed abstract


5. Torres A et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Inf Dis 2017 (15. Dezember 2017, online) PubMed abstract


6. Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF. In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01904-17 PubMed abstract


7. Ito A et al. In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01454-17 FREE FULL TEXT


8. Tillotson GS. Trojan Horse Antibiotics-A Novel Way to Circumvent Gram-Negative Bacterial Resistance? Infect Dis (Auckl). 2016 Oct 11;9:45-52. FREE FULL TEXT


Literaturangaben zum Übersichtsartikel aus

Heft 6 / 2017 der Zeitschrift für Infektionstherapie

Inhalative Antibiotika: Stellenwert bei Infektionen der tiefen Atemwege

1: Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am Thorac Soc. 2014 Mar;11(3):425-34 FREE FULL TEXT


2: Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999 Jan  7;340(1):23-30 FREE FULL TEXT


3: Wenzler E, Fraidenburg DR, Scardina T, Danziger LH. Inhaled Antibiotics for Gram-Negative Respiratory Infections. Clin Microbiol Rev. 2016 Jul;29(3):581-632 FREE FULL TEXT


4: Bassetti M, Luyt CE, Nicolau DP, Pugin J. Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Ann Intensive Care. 2016 Dec;6(1):35 FREE FULL TEXT


5: Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol. 2004 May;42(5):1915-22 FREE FULL TEXT


6: Niederman MS, Chastre J, Corkery K, Fink JB, Luyt CE, García MS. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med. 2012 Feb;38(2):263-71


7: Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review. Eur Respir J. 2014 Aug;44(2):382-93 FREE FULL TEXT


8: Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, O'Donnell A, Sahn SA, Smith LJ, Stewart JO, Abuan T, Tully H, Van Dalfsen J, Wells CD, Quan J. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):481-5


9: Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014 Apr 15;189(8):975-82 FREE FULL TEXT


10: Serisier DJ, Bilton D, De Soyza A, Thompson PJ, Kolbe J, Greville HW, Cipolla D, Bruinenberg P, Gonda I; ORBIT-2 investigators. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax. 2013 Sep;68(9):812-7 FREE FULL TEXT



11: Insmed, Inc. TR02-107 trialreport.

Available from:


12: Wilson R, Welte T, Polverino E, De Soyza A, Greville H, O'Donnell A, Alder J, Reimnitz P, Hampel B. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J. 2013 May;41(5):1107-15 FREE FULL TEXT


13: De Soyza A et al. Late-Breaking-Abstract: Respire I  Europ Respir J 2016; 48, Suppl 60


14: Aradigm Corporation: Memorandum July 27, 2017


15: Kollef MH, Micek ST. Recommendations for aerosolized antibiotics in ventilator-associated pneumonia and ventilator-associated tracheobronchitis: too  little and too late? Clin Microbiol Infect. 2017 Sep;23(9):593-595


16: Solé-Lleonart C, Rouby JJ, Blot S, Poulakou G, Chastre J, Palmer LB, Bassetti M, Luyt CE, Pereira JM, Riera J, Felton T, Dhanani J, Welte T, Garcia-Alamino JM, Roberts JA, Rello J. Nebulization of Antiinfective Agents in Invasively Mechanically Ventilated Adults: A Systematic Review and Meta-analysis. Anesthesiology. 2017 May;126(5):890-908


17: Rello J, Rouby JJ, Sole-Lleonart C, Chastre J, Blot S, Luyt CE, Riera J, Vos  MC, Monsel A, Dhanani J, Roberts JA. Key considerations on nebulization of antimicrobial agents to mechanically ventilated patients. Clin Microbiol Infect.  2017 Sep;23(9):640-646


18: Kollef M H et al. Chest 2017, in press


19: Niederman MS(1), Chastre J, Corkery K, Fink JB, Luyt CE, García MS.BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med. 2012 Feb;38(2):263-71


20: Rello J, Solé-Lleonart C, Rouby JJ, Chastre J, Blot S, Poulakou G, Luyt CE, Riera J, Palmer LB, Pereira JM, Felton T, Dhanani J, Bassetti M, Welte T, Roberts JA. Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European  Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect. 2017 Sep;23(9):629-639


Literaturangaben zum Übersichtsartikel aus

Heft 3 / 2017 der Zeitschrift für Infektionstherapie

Therapie von Helicobacter pylori-Infektionen

1. Warren JR Helicobacter: the ease and difficulty of a new discovery (Nobel lecture). ChemMedChem. 2006;1:672-85


2. Hentschel E et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med. 1993;328:308-12 FREE FULL TEXT


3. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017 Feb;112(2):212-239


4. Fischbach W S2k-Leitllinie Helicobacter pylori und gastroduodenale Ulkuskrankheit. Z Gastroenterol. 2016 Apr;54(4):327-63


5. Wüppenhorst N et al. Prospective multicentre study on antimicrobial resistance of Helicobacter pylori in Germany. J Antimicrob Chemother. 2014;69:3127-33


6. Regnath T, Raecke O, Enninger A, Ignatius R. Increasing metronidazole and rifampicin resistance of Helicobacter pylori isolates obtained from children and adolescents between 2002 and 2015 in southwest Germany. Helicobacter. 2017;22:e12327


7. Best LM et al. Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods. Antimicrob Agents Chemother. 2003 Oct;47(10):3138-44 FREE FULL TEXT


8. Malfertheiner P et al. . Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011 Mar 12;377(9769):905-13


9. Greenberg ER et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. 2011 Aug 6;378(9790):507-14 FREE FULL TEXT


10. Marin AC, Nyssen OP, McNicholl AG, Gisbert JP. Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. Drugs. 2017 May;77(7):765-776


Literaturangaben zum Übersichtsartikel aus

Heft 2 / 2017 der Zeitschrift für Infektionstherapie

Antiinfektive Therapie der Sepsis

1: Seymour CW, Liu VX, Iwashyna TJ et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):762-74


2: Rhodes A, Evans LE, Alhazzani W et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017 Mar;45(3):486-552


3: Panknin HT, Müller-Werdan U, Schröder S. Neue Sepsisdefinition. ProCare. 2016 Oct;21(8):22-5


4: Zhang D, Micek ST, Kollef MH. Time to Appropriate Antibiotic Therapy Is an Independent Determinant of Postinfection ICU and Hospital Lengths of Stay in Patients With Sepsis. Crit Care Med. 2015 Oct;43(10):2133-40


5: Pletz MW, Bloos F, Burkhardt O et al. Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock. Intensive Care Med.  2010 Jun;36(6):979-83


6: van Zanten AR, Polderman KH, van Geijlswijk IM, van der Meer GY, Schouten MA,  Girbes AR. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care. 2008 Sep;23(3):422-30


7: Roberts JA, Abdul-Aziz MH, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, Bellomo R, Lipman J. Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials. Am J Respir Crit Care Med. 2016 Sep 15;194(6):681-91


8: Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013 Sep 16;(9):CD001090


Literaturangaben zum Übersichtsartikel aus

Heft 1 / 2017 der Zeitschrift für Infektionstherapie

Optimale Dauer der Antibiotikatherapie – eine aktuelle Bestandsaufnahme

1. Armand-Lefèvre L et al. Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother. 2013;57:1488-95 FREE FULL TEXT


2. Rice LB The Maxwell Finland Lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and clostridium difficile. Clin Infect Dis. 2008;46:491-496


3. Spellberg B The New Antibiotic Mantra-"Shorter Is Better". JAMA Intern Med. 2016;176:1254-1255


4. Uranga A et al.  Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. JAMA Intern Med. 2016;176:1257-1265


5. Choudhury G et al. Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia-a propensity-adjusted analysis. Clin Microbiol Infect. 2011;17:1852-1858.


6. Dimopoulos G, Matthaiou DK. Duration of therapy of ventilator-associated pneumonia. Curr Opin Infect Dis. 2016;29:218-222


7. Sawyer RG et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015;372:1996-2005 FREE FULL TEXT



8. Bernard L et al. Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. Lancet. 2015;385:875-882


9. Lora-Tamayo J, Murillo O Shorter treatments for vertebral osteomyelitis. Lancet 2015;385:836-837


10. Hoberman A et al. Shortened antimicrobial treatment for acute otitis media in young children. N Engl J Med. 2016 Dec 22;375:2446-2456 FREE FULL TEXT.


Informationen für Ärzte und Apotheker zur rationalen Infektionstherapie

Die Zeitschrift für Infektionstherapie (bis 2015: "Zeitschrift für Chemo-therapie") erscheint im Jahr 2018 im 39. Jahrgang. Herausgeber und Redaktion sind bemüht, Sie kontinu-ierlich und aktuell über wichtige Entwicklungen im Bereich der Infektionstherapie zu informieren.


Die vollständigen, aktuellen Ausgaben der Zeitschrift sind nur im Abonnement erhältlich.


Nach 24 Monaten stehen die Hefte als PDF-Dateien  frei zur Verfügung (Frühere Ausgaben und Register).


Wir bieten Ihnen auf diesem Wege ebenfalls alle Artikel der Rubrik "Neueinführungen" und einige andere regelmäßige Beiträge aus der Zeitschrift an.


Letzte Aktualisierung dieser Seiten:

19. Mai 2018

Druckversion Druckversion | Sitemap
© Zeitschrift für Infektionstherapie